Trials / Unknown
UnknownNCT00139373
Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere · Academic / Other
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The syndrome of distractibility is a behavioral disorder induced by a lesion or a dysfunction of the frontal lobe. This sign is frequent in patients with progressive supranuclear palsy (PSP), a neurodegenerative disorder with severe neuronal loss in the prefrontal cortex and cholinergic systems, in particular in the Meynert basalis nucleus. This could participate in the occurrence of the distractibility in these patients. The aim of this study is to evaluate the effect of the donepezil, an anticholinesterase, on the distractibility in PSP patients, by using oculomotor and neuropsychological assessments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | donepezil |
Timeline
- First posted
- 2005-08-31
- Last updated
- 2007-09-14
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00139373. Inclusion in this directory is not an endorsement.